Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px
Document › Details

OSE Immunotherapeutics S.A.. (9/7/17). "Press Release: OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of its Product Portfolio". Nantes.

Organisations Organisation OSE Immunotherapeutics S.A.
  Today OSE Pharma S.A.
  Group OSE Immunotherapeutics (Group)
  Organisation 2 Janssen Biotech Inc. (JBI)
  Group Johnson & Johnson (JnJ) (Group)
Products Product Tedopi® cancer immunotherapy
  Product 2 FR104 MAb fragment (Effimmune)
Index term Index term Servier–OSE Immunotherapeutics: therapeutic antibody, 201612– license option ww excl up to €272m for Effi-7 immunomodulatory antibody to Servier
Persons Person Costantini, Dominique (OSE Pharma 201504 CEO + Co-founder + former CEO + Co-founder of BioAlliance Pharma in 1997)
  Person 2 de Weese, David (Paul Capital 201504 Director + Board Member of OSE Pharma)

Record changed: 2017-09-18


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for OSE Immunotherapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top